Breaking New Ground in Pancreatic Cancer

Exploratory subgroup analyses of the phase 2 DOVACC trial suggested a possible signal with the triplet in HRD-negative and PARP inhibitor–naive disease.

Perioperative nivolumab plus neoadjuvant chemotherapy did not significantly improve pCR rate or event-free survival in MIBC.

A protein called MPP8 helps drive chemotherapy resistance in the most-aggressive subtype of breast cancer, and suppressing its expression has the potential to improve treatment outcomes.

MajesTEC-9 data supported an EU indication expansion for teclistamab in relapsed/refractory multiple myeloma.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Readers share their opinions on some of the most talked-about lung cancer abstracts they’re looking forward to seeing at ESMO 2026.

Readers share their opinions on some of the most talked-about gynecologic cancer abstracts they’re looking forward to seeing at ESMO 2026.

Gastrointestinal oncologists weigh HER2 testing practices, the order of HER2-directed therapies, and emerging agents for metastatic colorectal cancer.